patients had cardiology follow-up (mean age 64 ± 20, 39% female) compared with 31 patients without follow up (mean age 61 ± 21, 50% female). There were no significant differences in the age, gender or presence of high-risk features in syncope between the two groups. Lack of ED discharge diagnosis (61% vs 44%, p 0.03) and prior syncopal presentations (59% vs 16%, p < 0.01) were significantly associated with outpatient follow up. Among patients with at least one high risk feature, only 50% received inpatient cardiac monitoring. Older age (72 ± 15 vs. 55 ± 24, p 0.03) and high-risk examination findings were significantly associated with monitoring.
High Risk
Discharged Background: Recurrences of idiopathic inflammatory pericarditis after an index event can cause substantial patient morbidity, and the need for corticosteroid therapy with its associated toxicities increases the risk of recurrence and harm. The anti-inflammatory medication colchicine is well-established in the treatment of recurrent inflammatory pericarditis at a maintenance dose (0.5 to 1 mg/day) for at least six months, with a favourable safety profile in most patients. However, despite this, recurrence rates remain as high as 30%.
Methods and Results: We report, for the first time, on the use of high-dose colchicine (1.5 to 3 mg/day in divided doses) therapy as a steroid-sparing strategy to further minimise recurrences and treatment-related morbidity. In a series of nine patients, we successfully and significantly reduced steroid requirements over five years without any increase in recurrence rates or colchicine-associated adverse events. Five out of nine patients did not require further corticosteroids after an initial trial of high-dose colchicine therapy, and four only required short periods of moderate doses during an acute flare.
Conclusion:
We propose that in carefully selected and monitored patients, escalation to high-dose colchicine therapy, with a subsequent gradual downtitration after achieving durable disease remission, can be safely instituted to minimise recurrences whilst also avoiding, weaning off, or reducing corticosteroid requirements. This novel steroidsparing approach needs to be further evaluated in an adequately powered, placebo-controlled randomised trial, with the study outcomes evaluating rate of recurrences but also accounting and adjusting for cumulative corticosteroid requirements. Background: Cardiovascular (CV) death is a leading cause of long-term mortality following liver transplantation (LT). Identifying pertinent CV risk factors that impact on long-term survival may allow an opportunity for intervention.
Methods: Outcome data was prospectively collected for all adult LT performed in Australia and New Zealand between 1985-2017, from the Australian and New Zealand Liver Transplant Registry. Risk factors including hypertension, diabetes, age, sex, obesity (body mass index ≥30 kg/m 2 ), pre-existing coronary artery disease (CAD) and non-alcoholic fatty liver disease aetiology were entered in a multivariable Cox model.
Results: Among 4,538 adult LT performed across 6 participating centres, 1433 (31.6%) deaths occurred. This included 240 CV deaths (17%) that occurred over a median follow-up of 10.5 years (IQR: 4.9-17.9 years). On univariate analysis, age ≥50 years (log-rank test, p < 0.001), diabetes (p < 0.001) and obesity (p = 0.006) were associated with all-cause mortality (Figure) . After Cox multivariable adjustment, diabetes (Hazard ratio [HR] 1.4, 95%CI 1.07-1.8, p = 0.01) and age ≥50 (HR 1.5 95%CI 1.2-1.9, p < 0.001) remained as independent predictors for all-cause mortality. Notably, pre-existing CAD did not predict long-term mortality (p = 0.24).
Conclusion: Presence of diabetes and age ≥50 independently increased the risk of long term mortality following LT. Whether intensive risk factor modification in high-risk populations improves long-term survival after LT remains to be tested.
